This website uses cookies, including third party ones, to allow for analysis of how people use our website in order to improve your experience and our services. By continuing to use our website, you agree to the use of such cookies. Click here for more information on our and .
Healthcare
Asia-Pacific products are in later stages of development compared to other markets
Melbourne – 11th October 2010 – Asia-Pacific products are in later stages of development compared to other markets, but still comprise only 15% of global products in development according to MedTRACK, a market leading database of private and public biomedical companies. The volume of products in development in the Asia-Pacific region still lags behind North…
11 Oct 2010, by Informa InsightsHealthcare
Implications of Nivestim’s approval on the Australian biosimilars market
Melbourne – 6th October 2010 – Biosimilars in Australia: Nivestim approval opens up local filgrastim biosimilars market. Lisette Oversteegen, Lead Analyst, comments: “Although the recent approval of biosimilar filgrastim is a positive development for the Australian industry, the proposed biosimilars pricing regulations may slow uptake”. Compared with Europe, where several biosimilar products of three different…
6 Oct 2010, by Informa InsightsHealthcare
The Australian reimbursement committee is set to consider Novo Nordisk’s type 2 diabetes treatment
Melbourne – 5th October 2010 - Novo Nordisk: swift approval of Victoza for reimbursement is vital to the drug's success. Lisette Oversteegen, Lead Analyst, comments: “For a prescription drug to be commercially successful in Australia, being included on the country's government reimbursement list, the Pharmaceutical Benefits Scheme (PBS) is essential”. In its November meeting, the…
5 Oct 2010, by Informa InsightsHealthcare
Biologic treatments for rheumatoid arthritis to capture greater market share
[tweetmeme source= "informa_oz" only_single=false] Melbourne, 30th September 2010 - Use of biologic disease-modifying antirheumatic drugs (DMARDs) in the treatment of rheumatoid arthritis is set to increase dramatically over the next five years finds independent market analyst, Datamonitor. Despite their considerable cost, rheumatologists interviewed by Datamonitor in the US, Europe and Japan expect a continued increase…
30 Sep 2010, by Informa InsightsHealthcare
Venture Financing in Asia-Pacific looks promising
[tweetmeme source= "informa_oz" only_single=false] Melbourne – 28th September 2010 – MedTRACK, a market leading database of private and public biomedical companies, reports that the number of transactions in the Asia-Pacific region is on pace to rebound by 15% in 2010. Sarah Terry, President of MedTRACK comments: To be a company in Asia-Pacific region is really…
28 Sep 2010, by Informa InsightsHealthcare
Antidyslipidemics | End of an Era
[tweetmeme source= "informa_oz" only_single=false] The domination of the antidyslipidemic market by five top brands is set to fundamentally change over the next 10 years as novel agents fail to meet the success of their predecessors, claims a new report from independent market analyst, Datamonitor. The top five antidyslipidemic brands: Lipitor (atorvastatin, Pfizer), Crestor (rosuvastatin, AstraZeneca),…
28 Sep 2010, by Informa InsightsHealthcare
Cancer Targeted Therapies and Immunotherapies | Resisting Competitive Pressures
[tweetmeme source= "informa_oz" only_single=false] Drug developers aiming to emulate the success of cancer targeted therapies and immunotherapy brands will struggle as a result of heightened competition and pharmacoeconomic constraints, suggests independent market analyst, Datamonitor. Over the last decade the targeted therapies and immunotherapies class has fuelled growth in the oncology market, making it very attractive…
28 Sep 2010, by Informa InsightsHealthcare
J&J in Talks to Buy Crucell | Expert Analyst Comment
[tweetmeme source= "informa_oz" only_single=false] Johnson & Johnson is in advanced negotiations to buy Dutch biotechnology company Crucell NV for €1.75 billion ($2.29 billion), the two companies said today. Giles Somers, senior healthcare analyst at Datamonitor comments: “So, one more big Pharma enters the vaccines space – following the example of Pfizer (through the acquisition of…
28 Sep 2010, by Informa InsightsHealthcare
Multi-blockbuster sales expected as Gilenya changes Multiple Sclerosis landscape
[tweetmeme source= "informa_oz" only_single=false] Melbourne, 23rd September 2010 - Gilenya is set to become the leading treatment in multiple sclerosis (MS) with multi-blockbuster sales, ending the decade long dominance of interferon betas and Copaxone (glatiramer acetate, Teva) says Trung Huynh, healthcare analyst at Datamonitor. “The FDA approved Novartis’s Gilenya (formally Gilenia; fingolimod) yesterday. It is…
28 Sep 2010, by Informa InsightsEducation | Healthcare
new subgroups on Linkedin!
[tweetmeme source= "informa_oz" only_single=false] Exciting news everyone! We're slowly reorganising our groups and subgroups in Linkedin and will be updating the blog to keep YOU update on the latest subgroups created so that you can connect with the industry/sector that you want to! We've created 2 new subgroups under the Informa Healthcare Community parent group.…
22 Sep 2010, by Informa InsightsInforma Connect Australia is the nation's leading event organiser. Our events comprise of large scale exhibitions, industry conferences and highly specialised corporate training.
